Risk Factors for Community- and Workplace Transmission of COVID-19 : Risk Factors for Community- and Workplace Transmission of COVID-19
Summary The data collected will identify real-life risk factors for getting the COVID-19 diagnosis.The Oslo University Hospital/University of Oslo web-based solution "nettskjema" will be used to collect data and consent forms.The impact of knowing the risk factors for COVID-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus.Detailed description Research into an ongoing COVID-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (PPE) supplies are limited. The risk of transmission to study personal is non-negligible even when PPE is available.A study design based on an electronic questionnaire and consent from delivered from the Oslo University Hospital/University of Oslo, GDPR (General Data Protection Regulation) compliant "TSD" service has therefore been chosen.The study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification.The groups that will be included are:Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the diseaseHospitalized patients without COVID-19Healthcare personal or other groups with an increased risk of COVID-19Healthy volunteersParticipants may be followed with repeated questionnaires prospectively.Biological samples Biological samples may hold crucial information about the susceptibility to COVID-19 and for susceptibility to the progression of the disease. It is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. The material will be analyzed with non-genetic methods most suitable to provide such information..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 13. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: March 25, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 20, 2021, Last updated: December 22, 2021 |
|---|
| Study ID: |
NCT04320732 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003339955 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003339955 | ||
| 003 | DE-627 | ||
| 005 | 20230426001432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003339955 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04320732 | ||
| 035 | |a (UBBS_Klinische_Studien)REK-124170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Risk Factors for Community- and Workplace Transmission of COVID-19 |b Risk Factors for Community- and Workplace Transmission of COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: March 25, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 20, 2021, Last updated: December 22, 2021 | ||
| 520 | |a Summary The data collected will identify real-life risk factors for getting the COVID-19 diagnosis.The Oslo University Hospital/University of Oslo web-based solution "nettskjema" will be used to collect data and consent forms.The impact of knowing the risk factors for COVID-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus.Detailed description Research into an ongoing COVID-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (PPE) supplies are limited. The risk of transmission to study personal is non-negligible even when PPE is available.A study design based on an electronic questionnaire and consent from delivered from the Oslo University Hospital/University of Oslo, GDPR (General Data Protection Regulation) compliant "TSD" service has therefore been chosen.The study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification.The groups that will be included are:Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the diseaseHospitalized patients without COVID-19Healthcare personal or other groups with an increased risk of COVID-19Healthy volunteersParticipants may be followed with repeated questionnaires prospectively.Biological samples Biological samples may hold crucial information about the susceptibility to COVID-19 and for susceptibility to the progression of the disease. It is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. The material will be analyzed with non-genetic methods most suitable to provide such information. | ||
| 650 | 2 | |a Coronavirus Infections | |
| 650 | 4 | |a Medical Condition: Coronavirus | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 13. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:13 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04320732 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 13 |c 12 | ||